ALCIDION GROUP LIMITED (ALC)
Share Price Analysis and Chart

02/11/2026

1

Buy

$0.15

36.36%

Alcidion has FY27 contracted revenue of $50m following the NCA contract expansion and, as Bell Potter observes, this is already not far off the $51.6m of annual revenue reported in FY26. FY27 guidance is retained for revenue and EBITDA (FY26 was $6.8m) to exceed FY26.

The broker notes, separately, the recently announced buyback of up to 10% of shares reflects confidence in the balance sheet and future cashflow profile.

A new, internally developed Patient Admin System provides the potential upsell for existing PCS customers and an even stronger offering. Buy rating and 15c target maintained.

FORECAST
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.20 cents.
Bell Potter forecasts a full year FY28 dividend of 0.00 cents and EPS of 0.30 cents.

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

21/08/2026

1

Buy

$0.17

54.55%

Moelis Australia maintains a Buy rating for Alcidion Group with its target price increased to $0.17 from $0.16 following a strong FY26 result that demonstrates robust financial turnaround and growth.

Management enters FY27 with revenue visibility supported by contracts covering roughly 85% of estimated revenue.

Total contract value wins exceeding $140m over the past two years have established a larger recurring revenue base, enhancing earnings quality and reducing reliance on large upfront licence sales.

The broker's estimates reflect upward revisions to net profit after tax and earnings per share across FY27 and FY28, underpinned by diverse growth opportunities across the UK, Australia, and international markets.

FORECAST
Moelis forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.20 cents.
Moelis forecasts a full year FY28 dividend of 0.00 cents and EPS of 0.30 cents.